Shots:
- Swissmedic has approved Vimkunya (recombinant, adsorbed) for active immunization against CHIKV disease in individuals (≥12yrs.)
- Vimkunya is a single-dose, prefilled VLP-based chikungunya vaccine for individuals ≥12 years, designed to trigger rapid immunity with responses starting as early as 1 week
- Bavarian Nordic has submitted a Health Canada application, with potential chikungunya vaccine approval in H1’26
Ref: Bavarian Nordic | Image: Bavarian Nordic | Press Release
Related News: Bavarian Nordic Reports the MHRA’s Approval of Vimkunya to Prevent Chikungunya
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
